Cargando…

A pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma

PURPOSE: Neutropenia is a common complication from chemotherapy, limiting optimal dosing and treatment. Lipegfilgrastim is a long-acting granulocyte colony-stimulating factor developed for the management of chemotherapy-induced neutropenia. The objectives of this phase 1, multinational, open-label,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belogurova, Margarita B., Kizyma, Zoryana P., Garami, Miklós, Csóka, Mónika, Lamson, Michael J., Buchner, Anton, Bias, Peter, Lammerich, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225185/ https://www.ncbi.nlm.nih.gov/pubmed/27986986 http://dx.doi.org/10.1007/s00280-016-3216-2

Ejemplares similares

A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy
por: Buchner, Anton, et al.
Publicado: (2014)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study
por: Link, Hartmut, et al.
Publicado: (2020)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
por: Bondarenko, Igor, et al.
Publicado: (2013)

Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy
por: Zou, Linglong, et al.
Publicado: (2016)

Review on lipegfilgrastim
por: Gasparic, Maja, et al.
Publicado: (2015)

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy
por: Volovat, Constantin, et al.
Publicado: (2015)

Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women
por: Lammerich, Andreas, et al.
Publicado: (2015)

LINC-41. TREATMENT OF RECURRENT MEDULLOBLASTOMA IN CHILDREN IN LOW INCOME SETTINGS
por: Kizyma, Roman, et al.
Publicado: (2020)

Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f(®) in healthy women after follicle-stimulating hormone downregulation
por: Lammerich, Andreas, et al.
Publicado: (2015)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
por: Hoggatt, Jonathan, et al.
Publicado: (2015)

Rhabdomyosarcoma and Extraosseous Ewing Sarcoma
por: Gurria, Juan P., et al.
Publicado: (2018)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
Publicado: (2015)

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
por: Guariglia, Roberto, et al.
Publicado: (2016)

An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer
por: Rashed, Ahmed, et al.
Publicado: (2023)

Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma
por: Yu, Peter Y., et al.
Publicado: (2017)

Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting
por: Merseburger, Axel S., et al.
Publicado: (2021)

Primary alveolar rhabdomyosarcoma of the bone: two cases and review of the literature
por: Balogh, Petra, et al.
Publicado: (2016)

Up-regulation of GLI1 in vincristine-resistant rhabdomyosarcoma and Ewing sarcoma
por: Yoon, Joon Won, et al.
Publicado: (2020)

Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma
por: van Erp, Anke E. M., et al.
Publicado: (2022)

Prescribing patterns from medical chart abstraction of patients administered lipegfilgrastim: a pilot study in Europe
por: Kaplan, Sigal, et al.
Publicado: (2019)

Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events
por: Bond, T Christopher, et al.
Publicado: (2017)

Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review
por: Rijs, Zeger, et al.
Publicado: (2021)

Characterization of mTOR Activity and Metabolic Profile in Pediatric Rhabdomyosarcoma
por: Felkai, Luca, et al.
Publicado: (2020)

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
por: Akpo, Esse I. H., et al.
Publicado: (2017)

Current and Future Treatment Strategies for Rhabdomyosarcoma
por: Chen, Celine, et al.
Publicado: (2019)

Survival Outcomes of Ewing Sarcoma and Rhabdomyosarcoma by High- versus Low-Volume Cancer Centres in British Columbia, Canada
por: Yeo, Sarah, et al.
Publicado: (2023)

Primary pediatric endobronchial Ewing sarcoma family of tumors
por: Hayakawa, Akira, et al.
Publicado: (2013)

IDH Mutation Analysis in Ewing Sarcoma Family Tumors
por: Na, Ki Yong, et al.
Publicado: (2015)

Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration
por: Galecio, Juan Sebastián, et al.
Publicado: (2020)

EWS/ETS Regulates the Expression of the Dickkopf Family in Ewing Family Tumor Cells
por: Miyagawa, Yoshitaka, et al.
Publicado: (2009)

Pharmacokinetics of tulathromycin in pregnant ewes (Ovis aries) challenged with Campylobacter jejuni
por: Yaeger, Michael, et al.
Publicado: (2021)

Role of Radiotherapy in the Multimodal Treatment of Ewing Sarcoma Family Tumors
por: Choi, Yunseon, et al.
Publicado: (2015)

Getting control during follow-up visits: the views and experiences of parents on tumor surveillance after their children have completed therapy for rhabdomyosarcoma or Ewing sarcoma
por: Vaarwerk, B., et al.
Publicado: (2019)

Expression of members of the myf gene family in human rhabdomyosarcomas.
por: Clark, J., et al.
Publicado: (1991)

Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial
por: Tjulandin, Sergei A, et al.
Publicado: (2011)

Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial
por: Tjulandin, Sergei A, et al.
Publicado: (2010)

Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF
por: Lehmacher, W., et al.
Publicado: (2016)

Body temperature: Its regulation in framework of energy balance
por: Garami, András, et al.
Publicado: (2014)

Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary
por: Müller, Judit, et al.
Publicado: (2022)

STAT3 Regulates Proliferation and Immunogenicity of the Ewing Family of Tumors In Vitro
por: Behjati, Sam, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3fsjced9foo581sn6c1j61lpij